In 2005, a class action was brought against Pfizer Canada ULC and Pfizer inc. (collectively “Pfizer”) alleging that the latter misrepresented the risks associated with the use of Depo-Provera, an injectable form of birth control, by failing to indicate that people who use Depo-Provera may experience a significant and possibly irreversible bone mineral density loss that could lead to osteopenia or osteoporosis.
Depo-Provera is still on sale in Canada, but its packaging and patient information have been updated to describe this risk.
In may 2021, the parties have agreed to settle the Class Action, for a total settlement amount of $2,176,250.00. The Settlement Agreement provides for Pfizer to compensate members who have filed a claim for their loss of bone mineral density and, if applicable, for their fracture, depending on severity and duration. During the year 2023, the claims administrator proceeded with the distribution of compensation to eligible class members.
The case is now closed.